BRPI0607840A2 - uso de uma composição imunogência, e de um antìgeno de vzv, vacina ou composição imunogênica, e, kit - Google Patents

uso de uma composição imunogência, e de um antìgeno de vzv, vacina ou composição imunogênica, e, kit

Info

Publication number
BRPI0607840A2
BRPI0607840A2 BRPI0607840-0A BRPI0607840A BRPI0607840A2 BR PI0607840 A2 BRPI0607840 A2 BR PI0607840A2 BR PI0607840 A BRPI0607840 A BR PI0607840A BR PI0607840 A2 BRPI0607840 A2 BR PI0607840A2
Authority
BR
Brazil
Prior art keywords
composition
vaccine
kit
immunogenic composition
vzv
Prior art date
Application number
BRPI0607840-0A
Other languages
English (en)
Inventor
Emmanuel Jules Hanon
Jean Stephenne
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34430592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0607840(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of BRPI0607840A2 publication Critical patent/BRPI0607840A2/pt
Publication of BRPI0607840B1 publication Critical patent/BRPI0607840B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

USOS DE UMA COMPOSIçãO IMUNOGêNICA, E DE UM ANTìGENO DE VZV, VACINA OU COMPOSIçãO IMUNOGêNICA, E, KIT. Uso de uma composição imunogênica compreendendo VZV gE, ou um fragmento imunogênico do mesmo, e um adjuvante TH- 1 na preparação de um medicamento para a prevenção ou a melhoria de herpes-zoster e/ou de neuralgia pós-herpética. Composições compreendendo um antígeno VZV gE truncado e um adjuvante contendo QS21, colesterol e MIPL 3D também são descritos.
BRPI0607840-0A 2005-03-03 2006-03-01 Uso de uma composição imunogênica, e, kit BRPI0607840B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0504436.7 2005-03-03
GBGB0504436.7A GB0504436D0 (en) 2005-03-03 2005-03-03 Vaccine
PCT/EP2006/002070 WO2006094756A2 (en) 2005-03-03 2006-03-01 Varicella zoster virus vaccine

Publications (2)

Publication Number Publication Date
BRPI0607840A2 true BRPI0607840A2 (pt) 2009-06-13
BRPI0607840B1 BRPI0607840B1 (pt) 2021-06-29

Family

ID=34430592

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607840-0A BRPI0607840B1 (pt) 2005-03-03 2006-03-01 Uso de uma composição imunogênica, e, kit

Country Status (35)

Country Link
US (3) US20080171079A1 (pt)
EP (4) EP1858917B8 (pt)
JP (2) JP5420842B2 (pt)
KR (2) KR101357204B1 (pt)
CN (2) CN101189254B (pt)
AR (2) AR052498A1 (pt)
AU (1) AU2006222225B2 (pt)
BR (1) BRPI0607840B1 (pt)
CA (2) CA2882255C (pt)
CY (5) CY1116108T1 (pt)
DK (4) DK1858917T3 (pt)
EA (1) EA011884B1 (pt)
ES (4) ES2675054T3 (pt)
GB (1) GB0504436D0 (pt)
HK (1) HK1111427A1 (pt)
HR (4) HRP20150142T1 (pt)
HU (4) HUE032544T2 (pt)
IL (1) IL185442A (pt)
LT (4) LT2301955T (pt)
LU (1) LUC00087I2 (pt)
MA (1) MA29714B1 (pt)
MX (2) MX346865B (pt)
MY (1) MY148464A (pt)
NL (1) NL300951I2 (pt)
NO (1) NO341841B1 (pt)
NZ (1) NZ561075A (pt)
PE (2) PE20100658A1 (pt)
PL (4) PL2281831T3 (pt)
PT (4) PT1858917E (pt)
SI (4) SI1858917T1 (pt)
TR (2) TR201809397T4 (pt)
TW (1) TWI403517B (pt)
UA (1) UA94900C2 (pt)
WO (1) WO2006094756A2 (pt)
ZA (1) ZA200707144B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CN101801412A (zh) * 2007-07-19 2010-08-11 诺瓦瓦克斯股份有限公司 水痘带状疱疹病毒-病毒样颗粒(vlp)和抗原
FR2952825B1 (fr) 2009-11-24 2012-05-25 Goaster Jacqueline Le Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2
PT2591114T (pt) 2010-07-06 2016-08-02 Glaxosmithkline Biologicals Sa Imunização de mamíferos de grande porte com doses baixas de arn
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
WO2012006378A1 (en) 2010-07-06 2012-01-12 Novartis Ag Liposomes with lipids having an advantageous pka- value for rna delivery
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
LT4066855T (lt) 2010-08-31 2023-03-10 Glaxosmithkline Biologicals Sa Pegilintos liposomos, skirtos imunogeną koduojančios rnr tiekimui
ES2716243T3 (es) 2010-10-11 2019-06-11 Glaxosmithkline Biologicals Sa Plataformas de suministro de antígenos
ES2656050T3 (es) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Composiciones de combinación inmunogénica y usos de las mismas
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9962439B2 (en) 2013-10-03 2018-05-08 Nitto Denko Corporation Injectable vaccine composition
JP6499420B2 (ja) * 2014-11-13 2019-04-10 公益財団法人ヒューマンサイエンス振興財団 ワクチン及び感染防御キット
US20180008700A1 (en) * 2014-12-18 2018-01-11 Glaxosmithkline Biologicals S.A. Vaccination
BE1022523B1 (fr) * 2014-12-18 2016-05-20 Glaxosmithkline Biologicals Sa Vaccination
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
TW201729838A (zh) * 2015-10-22 2017-09-01 現代公司 用於水痘帶狀疱疹病毒 (vzv)之核酸疫苗
US20180327436A1 (en) 2015-11-06 2018-11-15 Adjuvance Technologies, Inc. Triterpene saponin analogues
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. INFLUENZA VACCINE
WO2018097642A1 (ko) * 2016-11-25 2018-05-31 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
KR102028463B1 (ko) 2016-11-25 2019-10-04 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스 백신
CN107022559A (zh) * 2016-12-08 2017-08-08 长春祈健生物制品有限公司 一种水痘‑带状疱疹病毒糖蛋白e胞外区蛋白的制备方法
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
PE20191547A1 (es) * 2016-12-26 2019-10-24 Mogam Inst Biomedical Res Composicion de vacuna contra el herpes zoster
CN108727503A (zh) * 2017-04-18 2018-11-02 武汉博沃生物科技有限公司 VZV重组gE-鞭毛素融合蛋白及其制备方法和应用
CN110730666A (zh) * 2017-04-25 2020-01-24 佐剂技术公司 三萜皂苷类似物
SG11201909584QA (en) * 2017-04-25 2019-11-28 Adjuvance Technologies Inc Triterpene saponin analogues
US20210187098A1 (en) 2017-04-28 2021-06-24 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
CN111032080A (zh) 2017-05-30 2020-04-17 葛兰素史密丝克莱恩生物有限公司 用于制造佐剂的新型方法
US11324821B2 (en) 2017-10-16 2022-05-10 Adjuvance Technologies, Inc. Triterpene saponin analogues
WO2019106192A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
CN108315344A (zh) * 2018-02-14 2018-07-24 武汉博沃生物科技有限公司 Vzv糖蛋白e基因表达载体及其重组酵母菌株与应用
KR102337922B1 (ko) 2018-04-19 2021-12-09 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
KR20190121956A (ko) 2018-04-19 2019-10-29 가천대학교 산학협력단 담팔수 추출물에서 분리한 화합물을 유효성분으로 함유하는 수두-대상포진 바이러스 억제용 약학적 조성물
WO2019225962A1 (ko) * 2018-05-23 2019-11-28 재단법인 목암생명과학연구소 바리셀라 조스터 바이러스의 항원 변이체 및 이의 용도
MX2021001479A (es) 2018-08-07 2021-04-28 Glaxosmithkline Biologicals Sa Novedosos procesos y vacunas.
CN108992667A (zh) * 2018-08-09 2018-12-14 安徽智飞龙科马生物制药有限公司 一种带状疱疹疫苗及其制备方法、应用
KR102270048B1 (ko) * 2020-07-10 2021-06-28 주식회사 녹십자 바리셀라 조스터 바이러스 표면 단백질 항원의 생산 방법
EP3868399A4 (en) * 2018-09-27 2022-07-20 Bravovax Co., Ltd. IMMUNE COMPOSITION, METHOD FOR PREPARATION AND ASSOCIATED APPLICATION
US20220339282A1 (en) 2018-11-29 2022-10-27 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
CN109602901B (zh) * 2019-01-08 2022-05-27 成都迈科康生物科技有限公司 一种带状疱疹病毒疫苗及其制备方法和应用
EP3980044A1 (en) 2019-06-05 2022-04-13 GlaxoSmithKline Biologicals SA Saponin purification
CN112142828B (zh) * 2019-06-28 2022-02-01 怡道生物科技(苏州)有限公司 一种gE基因及表达该基因的载体
JP2023506439A (ja) * 2019-12-13 2023-02-16 遠大賽威信生命科学（南京）有限公司 医薬組成物及びその用途
US20230110839A1 (en) * 2020-02-28 2023-04-13 Celltrion Inc. Varicella zoster virus fusion protein and immunogenic composition comprising same
MX2023001586A (es) 2020-08-07 2023-05-03 Access To Advanced Health Inst Saponinas purificadas y proceso cromatografico para purificacion de las mismas.
KR102660479B1 (ko) * 2020-09-11 2024-04-25 주식회사 유바이오로직스 수두 또는 대상포진 백신 조성물 및 이를 이용하는 방법
RU2750818C1 (ru) * 2020-11-19 2021-07-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова Вирусный штамм для получения аттенуированной живой культуральной вакцины для профилактики и лечения опоясывающего герпеса для взрослого населения
WO2023056912A1 (en) * 2021-10-08 2023-04-13 Suzhou Abogen Biosciences Co., Ltd. Nucleic acid vaccines for vzv
WO2023064612A2 (en) 2021-10-15 2023-04-20 BioNTech SE Pharmaceutical compositions for delivery of viral antigens and related methods
WO2023096963A1 (en) 2021-11-24 2023-06-01 Flagship Pioneering Innovations Vi, Llc Varicella-zoster virus immunogen compositions and their uses
CN116350770A (zh) * 2021-12-28 2023-06-30 成都迈科康生物科技有限公司 一种带状疱疹疫苗制剂及其制备方法
WO2024017827A1 (en) 2022-07-19 2024-01-25 Glaxosmithkline Biologicals Sa Continuous process for vaccine production
CN116655748A (zh) * 2023-02-28 2023-08-29 易慧生物技术(上海)有限公司 一种截短型水痘-带状疱疹病毒gE蛋白及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (pt) 1974-03-12 1978-11-01
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4769239A (en) 1984-08-21 1988-09-06 Merck & Co., Inc. Vaccine against varicella-zoster virus
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0405867B1 (en) 1989-06-27 1995-03-15 SMITHKLINE BEECHAM BIOLOGICALS s.a. Novel compounds
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CA2085827C (en) 1991-12-23 2003-10-14 Lucas A. T. Hilgers Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
DK0761231T3 (da) 1992-06-25 2000-05-08 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
JP4562812B2 (ja) 1992-07-17 2010-10-13 メルク・シャープ・エンド・ドーム・コーポレイション 帯状疱疹の予防または水痘関連ヘルペス後神経痛の緩和方法
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
US5976552A (en) * 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
MX9707021A (es) * 1995-03-23 1997-11-29 Immunex Corp Receptor de il-7.
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
KR0177323B1 (ko) * 1996-02-16 1999-04-01 성재갑 바이러스 백신 생산에 유용한 사람 이배체 폐세포 및 이를 이용한 수두 백신의 제조방법
IL132126A0 (en) 1997-04-01 2001-03-19 Ribi Immunochem Research Inc Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
GB9901254D0 (en) * 1999-01-20 1999-03-10 Smithkline Beecham Biolog Vaccines
PL208755B1 (pl) * 2000-10-18 2011-06-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
CN103028113A (zh) 2013-04-10
MX346865B (es) 2017-04-04
LUC00087I2 (pt) 2018-11-26
PL2281830T3 (pl) 2017-06-30
HUE038467T2 (hu) 2018-10-29
CY1120347T1 (el) 2018-12-12
SI2281831T1 (en) 2018-07-31
CN103028113B (zh) 2015-05-20
LT2281831T (lt) 2018-07-10
WO2006094756A2 (en) 2006-09-14
EA011884B1 (ru) 2009-06-30
IL185442A (en) 2013-07-31
TWI403517B (zh) 2013-08-01
HRP20150142T1 (hr) 2015-05-22
CN101189254B (zh) 2013-05-22
CA2882255A1 (en) 2006-09-14
ES2675055T3 (es) 2018-07-06
HUS1800038I1 (hu) 2018-10-29
NO20074392L (no) 2007-11-27
AU2006222225B2 (en) 2012-08-16
AU2006222225A1 (en) 2006-09-14
PL2301955T3 (pl) 2018-08-31
EP2301955A2 (en) 2011-03-30
LT2301955T (lt) 2018-07-10
KR20140006115A (ko) 2014-01-15
PE20100658A1 (es) 2010-10-23
EP2281830A2 (en) 2011-02-09
LT2281830T (lt) 2017-02-10
BRPI0607840B1 (pt) 2021-06-29
CY2018025I1 (el) 2018-12-12
EP1858917B8 (en) 2015-05-06
KR20070110413A (ko) 2007-11-16
HRP20180988T1 (hr) 2018-08-10
ES2675054T3 (es) 2018-07-06
LTPA2018012I1 (lt) 2018-11-12
SI2281830T1 (sl) 2017-03-31
JP5840167B2 (ja) 2016-01-06
CA2600905C (en) 2015-05-05
GB0504436D0 (en) 2005-04-06
AR107285A2 (es) 2018-04-18
EP2281830B1 (en) 2016-12-21
CN101189254A (zh) 2008-05-28
PT1858917E (pt) 2015-02-24
DK1858917T3 (da) 2015-02-02
NL300951I1 (nl) 2018-09-26
HUE038468T2 (hu) 2018-10-29
TR201809393T4 (tr) 2018-07-23
DK2281831T3 (en) 2018-06-14
TR201809397T4 (tr) 2018-07-23
UA94900C2 (uk) 2011-06-25
KR101357204B1 (ko) 2014-02-06
CY1121211T1 (el) 2020-05-29
PL1858917T3 (pl) 2015-05-29
WO2006094756A3 (en) 2007-02-15
HK1111427A1 (en) 2008-08-08
PT2301955T (pt) 2018-06-18
HRP20170081T1 (hr) 2017-03-24
US20110104260A1 (en) 2011-05-05
EP2301955B1 (en) 2018-04-18
EP2281831A2 (en) 2011-02-09
HRP20180989T1 (hr) 2018-08-10
HUE032544T2 (en) 2017-10-30
NL300951I2 (nl) 2020-08-31
NZ561075A (en) 2009-06-26
DK2301955T3 (en) 2018-06-14
EP2281831B1 (en) 2018-04-18
CY2018025I2 (el) 2018-12-12
NO341841B1 (no) 2018-02-05
EP1858917A2 (en) 2007-11-28
JP2013144710A (ja) 2013-07-25
CY1118629T1 (el) 2017-07-12
EP1858917B1 (en) 2014-12-24
DK2281830T3 (en) 2017-03-20
JP5420842B2 (ja) 2014-02-19
CY1116108T1 (el) 2017-02-08
MA29714B1 (fr) 2008-09-01
US20080171079A1 (en) 2008-07-17
IL185442A0 (en) 2008-01-06
PE20061287A1 (es) 2006-12-07
MY148464A (en) 2013-04-30
PT2281830T (pt) 2017-02-24
PL2281831T3 (pl) 2018-08-31
PT2281831T (pt) 2018-06-15
EA200701632A1 (ru) 2008-02-28
TW200643028A (en) 2006-12-16
CA2882255C (en) 2018-03-27
EP2281830A3 (en) 2012-01-25
SI2301955T1 (en) 2018-07-31
CA2600905A1 (en) 2006-09-14
ES2532803T3 (es) 2015-03-31
AR052498A1 (es) 2007-03-21
SI1858917T1 (sl) 2015-03-31
EP2281831A3 (en) 2011-11-16
LTC2281831I2 (lt) 2020-08-25
EP2301955A3 (en) 2011-11-16
ES2618037T3 (es) 2017-06-20
US20110045059A1 (en) 2011-02-24
JP2008531637A (ja) 2008-08-14
ZA200707144B (en) 2009-11-25
US7939084B1 (en) 2011-05-10
MX2007010626A (es) 2007-10-16

Similar Documents

Publication Publication Date Title
BRPI0607840A2 (pt) uso de uma composição imunogência, e de um antìgeno de vzv, vacina ou composição imunogênica, e, kit
BRPI0621181A8 (pt) Substâncias imunogênicas que compreendem um adjuvante a base de ácido poliinosínico - ácido policitidílico
BRPI0619795B8 (pt) composição imunogênica, composição adjuvante, e, uso de uma composição imunogênica e um adjuvante
WO2007095976A3 (de) Adjuvanz in form einer lipid-modifizierten nukleinsäure
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
CL2008001103A1 (es) Compuestos derivados de [1,2,3]triazolo[4,5-b]piridin-corboxamidas y [1,2,3]triazolo[4,5-d]pirimidin-carboxamidas, inhibidores de megl y faah; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de dolores agudos o cronicos, vertigos, vomitos, nauseas, sindrome metabolico, dislipidemia, entre otros.
JP2008531637A5 (pt)
ECSP088591A (es) Anticuerpos anti-il-23 humanos, composiciones, metodos y usos
DK1898948T3 (da) Polyriboinosinsyre-polyribocytidylsyre-baseret adjuvans
CL2008001104A1 (es) Compuestos derivados de [1,2,3]triazolo[4,5-b]piridin-carboxamidas y [1,2,3]triazolo[4,5-d]pirimidin-carboxamidas, inhibidores de mgl y faah; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de delolores agudos o cronicos, vertigos, vomitos, nauseas, sindrome metaloico, dispipidemia, entre otros.
BRPI0807828B8 (pt) composição compreendendo leveduras e usos das mesmas, bem como método para o crescimento de leveduras e kit para o cultivo de leveduras
AR066395A1 (es) Reovirus que tienen secuencias modificadas
NO20092021L (no) Faste former inneholdende 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluor-fenylamino)-9H-purin-2-ylamino]-cykloheksan-1-ol, sammensetninger derav og anvendelse derav
UY27843A1 (es) Composicion de vacuna
BR122018075729B8 (pt) flavivírus na preparação de uma composição de vacina
CU23759A3 (es) Composiciones inmunogénicas
BRPI0510719A (pt) derivados de naftalimida, composição farmacêutica, uso e método de preparação dos mesmos
WO2006136460A3 (en) New adjuvant
BRPI0608430A2 (pt) composição adjuvante, processo para preparar a mesma e uso da mesma
BR112023019301A2 (pt) Formulações de vacina de coronavírus
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
BRPI0820258B8 (pt) composto, composições de vacina, e, uso de um composto
ATE538808T1 (de) Kombinierte dns/protein impfstoffzusammensetzungen
CL2008001102A1 (es) Compuestos derivados de [1,2,3]triazolo [4,5-b]piridina-carboxamidas, inhibidores de monoacilglicerol lipasa (mgl); procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso en el tratamiento de dolores agudos o cronicos, vertigos, vomitos, nauseas, sindrome metabolico, dislipidemia, entre otros.
CU23720A3 (es) Adyuvante basado en ácido poliinosínico-ácido policitidílico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/03/2006, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.